VYLDA M 500 15S

About

Vylda M 500 is a combination oral anti-diabetic medication containing Vildagliptin and Metformin hydrochloride, used for the management of type 2 diabetes mellitus. Vildagliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion and suppresses glucagon release by preserving active incretin levels. Metformin, a biguanide, primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues.

The synergistic action of these two agents provides comprehensive glycemic control, addressing multiple pathophysiological defects in type 2 diabetes. This combination is particularly useful for patients whose blood sugar levels are not adequately controlled with Metformin alone or who require a dual-action approach to achieve their glycemic targets. It helps to lower both fasting and post-meal blood glucose and HbA1c levels.

Uses

• Management of type 2 diabetes mellitus.
• Improving glycemic control in adults.
• When Metformin alone is insufficient.
• Reducing fasting and post-meal blood sugar.

Directions For Use

Take orally, usually twice daily with meals, as directed by your physician.

Benefits

• Dual mechanism for comprehensive control.
• Effective in lowering blood glucose and HbA1c.
• Addresses insulin resistance and secretion.
• Lower risk of hypoglycemia compared to sulfonylureas.
• Can lead to modest weight loss (due to Metformin).
• Convenient fixed-dose combination.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Vomiting
• Headache
• Dizziness
• Metallic taste
• Lactic acidosis (rare, serious)
• Vitamin B12 deficiency (long-term)
• Upper respiratory tract infection
• Nasopharyngitis
• Skin rash

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of lactic acidosis (a rare but serious side effect of Metformin) and hypoglycemia.
• Pregnancy - This combination is generally not recommended during pregnancy. Insulin therapy is usually preferred for glycemic control in pregnant women with diabetes.
• Breastfeeding - It is advised to avoid this combination during breastfeeding as both components may pass into breast milk. Consult a doctor.
• Liver - Use with caution in patients with liver impairment. Metformin is contraindicated in severe liver disease due to increased risk of lactic acidosis.
• Kidney - Metformin is contraindicated in severe kidney impairment (eGFR <30 mL/min/1.73m²) due to increased risk of lactic acidosis. Dose adjustment needed for moderate impairment.
• Lung - Use with caution in conditions causing hypoxia (e.g., severe lung disease, acute heart failure) as these can increase the risk of lactic acidosis with Metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.